Rc(=o)n Containing (i.e., Carboxamide) (r Is C Or H) Patents (Class 514/563)
  • Patent number: 10688042
    Abstract: A gel for topical application for alleviating food cravings is disclosed, which includes the steps of: periodically applying a gel topically to a user's skin, wherein said gel comprises: about 45.0 percent by weight of deionized water; about 10.0 percent by weight of benzyl alcohol; about 40.0 percent by weight of ethyl alcohol; about 0.2 percent by weight of tocopherol acetate; about 0.15 percent by weight of docosahexaenoic acid (DHA); about 1.15 percent by weight of resveratrol; about 1.0 percent by weight of a cross-linked polyacrylic acid copolymer; about 0.1 percent by weight of ethylenediaminetetraacetic acid (EDTA); about 200 ?L of lemon essential oil; and, from about 100 ?L to 200 ?L of triethanolamine.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: June 23, 2020
    Inventor: Antonino Cavallaro
  • Patent number: 10596167
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: March 24, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10555950
    Abstract: Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: February 11, 2020
    Assignee: SATIOGEN PHARMACEUTICALS, INC.
    Inventors: Andrew A. Young, Bronislava Gedulin, Howard E. Greene
  • Patent number: 10548857
    Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: February 4, 2020
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10532073
    Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: January 14, 2020
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Patent number: 10420738
    Abstract: An exemplary embodiment relates to novel protein modulators capable of altering function of the mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction. The invention provides compositions, pharmaceutical preparations and methods of correcting the cellular alteration of a mutant CFTR protein wherein the CFTR mutation is a mutation ?F508-CFTR, or another mutation of class II.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: September 24, 2019
    Assignee: INSTYTUT BIOCHEMII I BIOFIZYKI PAN
    Inventors: Norbert Odolczyk, Piotr Zielenkiewicz, Grzegorz Wieczorek, Aleksander Edelman, Danielle Tondelier, Janine Fritsch
  • Patent number: 10406086
    Abstract: Moisturizers including an acyl neutral amino acid having an acyl group with a carbon atom number of 2 to 18, and salts thereof, and cosmetics containing such a moisturizer promote the production of moisturizing-related proteins, such as filaggrin, involucrin, transglutaminase 1, keratin 10, and loricrin, and provide a moisturizing effect.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: September 10, 2019
    Assignee: Ajinomoto Co., Inc.
    Inventors: Gaku Hattori, Hiroji Ishii, Fumie Honkawa
  • Patent number: 10398667
    Abstract: Disclosed herein are methods for treating hair related disorders, including compounds that may be specific or modulate PPAR receptors.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: September 3, 2019
    Assignee: Nogra Pharma Limited
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • Patent number: 10111911
    Abstract: Compositions include one or more unsaturated fatty acids and one or more nitric oxide releasing compounds. Methods for using such compositions can enhance cognitive function, reduce or prevent a decline of social interaction, reduce or prevent age-related behavioral changes, increase trainability, maintain optimal brain function, facilitate learning and memory, reduce memory loss, retard brain aging, prevent or treat strokes, and/or prevent or treat dementia in an animal. Preferably, the compositions are food compositions useful for enhancing cognitive function in humans and companion animals.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: October 30, 2018
    Assignee: Nestec S.A.
    Inventor: Yuanlong Pan
  • Patent number: 10098860
    Abstract: Methods of treating renal cancer, including renal cell carcinoma, using bezafibrate are disclosed herein. Bezafibrate can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: October 16, 2018
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Kalpana Joshi, Jeevan Ghosalkar
  • Patent number: 9968576
    Abstract: The present invention relates to a neurodegenerative disease treatment use, which is a novel use of Ramalin, and, more specifically, to a composition for preventing or treating neurodegenerative diseases, containing Ramalin, which has an inflammasome and BACE1 expression inhibitory activity. Ramalin according to the present invention has an effect of improving a cognitive ability by inhibiting the expression of an inflammatory factor, which contains an NLRP inflammasome protein, and BACE1, and is thus useful for preventing or treating memory disorder and neurodegenerative diseases.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: May 15, 2018
    Assignee: KOREA INSTITUTE OF OCEAN SCIENCE AND TECHNOLOGY
    Inventors: Joung Han Yim, Il-Chan Kim, Se Jong Han, Dong-Gyu Jo
  • Patent number: 9849144
    Abstract: Pharmaceutical compositions comprising glutamine and trehalose for treating side effects to oncology treatments are disclosed.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: December 26, 2017
    Assignee: Healios Oncology Nutrition, LLC
    Inventor: Peter Meade Anderson
  • Patent number: 9839640
    Abstract: Methods for treating eye diseases associated with inflammation and/or vascular proliferation in subjects are disclosed. The methods include administering therapeutically effective amounts of a tranilast compound, in particular (E)-2-[[3-(3-Methoxy-4-propargyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or (E)-2-[[3,4-Bis(difluoromethoxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or pharmaceutically acceptable salts or solvates thereof.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: December 12, 2017
    Assignee: OccuRx Pty Ltd
    Inventors: Darren James Kelly, David Stapleton
  • Patent number: 9833426
    Abstract: An agent for enhancing NO production, comprising citrulline or a salt thereof and serine or a salt thereof as an active ingredient. An agent for preventing or ameliorating vascular endothelial malfunction, comprising citrulline or a salt thereof and serine or a salt thereof as an active ingredient. An agent for preventing or ameliorating a symptom caused by vascular endothelial malfunction, comprising citrulline or a salt thereof and serine or a salt thereof as an active ingredient.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: December 5, 2017
    Assignee: Kyowa Hakko Bio Co., Ltd.
    Inventors: Masahiko Morita, Miho Yin Komatsu, Takahiro Hara
  • Patent number: 9526713
    Abstract: Disclosed are uses of drugs for treating thrombocytopenia, in particular the use of dencichine in preparation of drugs for treating thrombocytopenia. By adding pharmaceutically acceptable conventional adjuvant material, dencichine can be prepared into an oral preparation or an injection. A pharmacodynamic trial shows that the dencichine can effectively inhibit the thrombocytopenia caused by chemotherapy drugs, and treat thrombocytopenic purpura with obvious curative effect and low toxic side effects.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: December 27, 2016
    Assignee: KUNMING SHENGHUO PHARMACEUTICAL (GROUP) CO., LTD.
    Inventors: Guihua Lan, Feng Lan, Xiaobo Sun
  • Patent number: 9518008
    Abstract: The present invention relates to (1S,2S,3S,4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentyl-1-carboxylic acid hydrates compounds, preparing methods thereof, pharmaceutical compositions containing said compounds and preparing methods thereof, and the clinical uses of said compounds as neuramidinase inhibitors for anti-influenza.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: December 13, 2016
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A., China
    Inventors: Song Li, Wu Zhong, Zhibing Zheng, Xinbo Zhou, Junhai Xiao, Yunde Xie, Lili Wang, Xingzhou Li, Guoming Zhao, Xiaokui Wang, Hongying Liu
  • Patent number: 9447028
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-amido-aryl compounds of the following formula (for convenience, collectively referred to herein as “AAA compounds”), which, inter alia, are (selective) retinoic acid receptor ? (RAR?) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RAR?, and in the treatment of diseases and conditions that are mediated by RAR?, that are ameliorated by the activation of RAR?, etc., including cognitive disorders, memory impairment, memory deficit, senile dementia, Alzheimer's disease, early stage Alzheimer's disease, intermediate stage Alzheimer's disease, late stage Alzheimer's disease, cognitive impairment, and mild cognitive impairment.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: September 20, 2016
    Assignee: King's College London
    Inventors: Jonathan Patrick Thomas Corcoran, Sarkis Barret Kalindjian, Alan David Borthwick, David Reginald Adams, Jane Theresa Brown, David Michel Adrien Taddei, Jason John Shiers
  • Patent number: 9409856
    Abstract: The present invention relates to a novel class of nuclear receptor binding agents (NRBAs). The NRBA compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including, inter alia, prevention and treatment of hormone-related diseases, cancers, inflammation, osteoporosis, peripheral vascular disease, reducing circulating lipid levels, and cardiovascular disease.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: August 9, 2016
    Assignee: Gtx, Inc.
    Inventors: James T. Dalton, Christina Herring, Duane D. Miller, Seoung-Soo Hong, Yali He, Michael L. Mohler, Ramesh Narayanan, Zhongzhi Wu
  • Patent number: 9402864
    Abstract: Methods of normalizing iron levels, treating iron deficiency and disorders related thereto, such as anemia, as described. Pharmaceutical compositions effective for such treatments are also described.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: August 2, 2016
    Assignee: EMISPHERE TECHNOLOGIES, INC.
    Inventors: Gary M. Riley, Parshuram Rath, Michael Novinski
  • Patent number: 9381196
    Abstract: The invention encompasses a compound derived from hydroxamic acid that may be used to slow the expansion of cancer cells and thus is effective in the treatment of cancer. Generally, the disclosed compound includes a benzimidazole group coupled to a hydroxyamide of five or more unsubstituted carbon atoms and any pharmaceutically acceptable salts, solvates and chemically protected forms thereof. Also disclosed are pharmacological compositions including the compound and methods of using the compound to slow the expansion of cancer cells as well as methods of using the compound to treat cancer.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: July 5, 2016
    Assignee: The Translational Genomics Research Institute
    Inventors: Tong Wang, Stephen Gately
  • Patent number: 9375438
    Abstract: Methods and compositions are provided that are utilized for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury. In particular, the methods and compositions are inhibitors of a particular NCca-ATP channel and include, for example, inhibitors of SURI and/or inhibitors of TRPM4. Kits for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury, are also provided. The present invention also concerns treatment and/or prevention of intraventricular hemorrhage in infants, including premature infants utilizing one or more inhibitors of the channel is provided to the infant, for example to brain cells of the infant.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: June 28, 2016
    Assignees: University of Maryland, Baltimore, The United States of America as Represented by the Dept. of Veterans Affairs
    Inventor: J. Marc Simard
  • Patent number: 9278062
    Abstract: An eye drop composition comprising a carboxyvinyl polymer and a monoterpene, and having a viscosity from 200 to 100,000 mPa·s. The monoterpene may be at least one selected from the group consisting of menthol, camphor and borneol. The carboxyvinyl polymer content may be from 0.001 to 10 w/v % with respect to the total volume of the eye drop composition, and the monoterpene content may be from 0.0001 to 1 w/v % with respect to the total volume of the eye drop composition.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: March 8, 2016
    Assignee: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Teiko Akagi, Takayuki Miyano, Motoyoshi Inooka
  • Patent number: 9272992
    Abstract: The present invention relates to (1S,2S,3S,4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentyl-1-carboxylic acid hydrates compounds, preparing methods thereof, pharmaceutical compositions containing said compounds and preparing methods thereof, and the clinical uses of said compounds as neuramidinase inhibitors for anti-influenza.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: March 1, 2016
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A., China
    Inventors: Song Li, Wu Zhong, Zhibing Zheng, Xinbo Zhou, Junhai Xiao, Yunde Xie, Lili Wang, Xingzhou Li, Guoming Zhao, Xiaokui Wang, Hongying Liu
  • Patent number: 9254271
    Abstract: A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that demonstrates substantial agonist activity at alpha adrenergic receptors and that is selected for peripheral (local) vasoconstriction and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for peripheral vasoconstriction and inhibition of pain and/or inflammation while avoiding undesirable side effects associated with systemic application of larger doses of the agents.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: February 9, 2016
    Assignee: Omeros Corporation
    Inventors: Gregory A. Demopulos, Pamela Pierce Palmer, Jeffrey M. Herz
  • Patent number: 9248186
    Abstract: A composition and method for treating nosebleed, that is, epistaxis. The composition comprises bismuth subgallate and a vasoconstriction agent, preferably oxymetazoline. The composition is preferably a paste administered intranasally.
    Type: Grant
    Filed: October 30, 2012
    Date of Patent: February 2, 2016
    Assignee: BINYARCO, LLC
    Inventor: Jeffrey E. Binder
  • Patent number: 9233089
    Abstract: Pulmonary arterial hypertension (PAH) can be prevented in persons susceptible to the diseases and PAH patients can be treated by administering an effective dose of a leukotriene inhibitor. Suitable inhibitors include leukotriene A4 hydrolase (LTA4H) inhibitors, leukotriene B4 receptor (BLT1/BLT2) antagonists, 5-lipoxygenase (5-LO) inhibitors, and 5-lipoxygenase activating protein (FLAP) inhibitors.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 12, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark R. Nicolls, Wen Tian, Jayakumar Rajadas
  • Patent number: 9187411
    Abstract: The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof. Also, the present invention provides a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The present invention further provides methods for treating abdominal aortic aneurysm or atherosclerosis comprising administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Formula (I) or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: November 17, 2015
    Assignee: Eli Lilly and Company
    Inventor: Douglas Richard Stack
  • Patent number: 9173907
    Abstract: A method of treating a fetus or embryo suspected of having a congenital condition that involves an abnormal or missing protein, the method has the steps of a. providing a plurality of human umbilical cord blood in a form suitable for intravenous administration; a b. administering the human umbilical cord blood cells to a mother carrying a fetus of embryo suspected of having said congenital condition. Such congenital conditions include Sanfilippo's syndrome, Hunter's syndrome, Hurler's syndrome, Tay-Sachs disease, Gaucher's disease, von Gierke's disease, Pompes disease, Cori disease, Andersen disease, McArdle's disease, Hers disease, Tauri's disease or Type IX glycogen storage disease.
    Type: Grant
    Filed: July 7, 2008
    Date of Patent: November 3, 2015
    Assignee: University of South Florida
    Inventors: Svitlana Garbuzova-Davis, Paul R. Sanberg, Sylvia Gografe
  • Patent number: 9084815
    Abstract: Disclosed is a method for treating tumor in a mammalian subject, which comprises administering a combination of (a) an anti-tumor agent and (b) a fatty acid derivative represented by the formula (I): to the subject in need thereof. The application also discloses a method for treating damages, especially gastrointestinal damages including mucositis such as stomatitis induced by an anti-tumor agent, wherein the method comprises administering a fatty acid derivative of formula (I) to the subject who is receiving the anti-tumor agent.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: July 21, 2015
    Assignee: SUCAMPO AG
    Inventor: Ryuji Ueno
  • Publication number: 20150148347
    Abstract: A compound of formula I, wherein the groups R1, R2, R3, X, m, and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
    Type: Application
    Filed: November 25, 2014
    Publication date: May 28, 2015
    Inventors: Iain LINGARD, Dieter HAMPRECHT
  • Publication number: 20150148395
    Abstract: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Application
    Filed: January 29, 2015
    Publication date: May 28, 2015
    Applicant: ALLERGAN, INC.
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • Publication number: 20150147282
    Abstract: The present invention relates to topical bioadhesive formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.
    Type: Application
    Filed: November 24, 2014
    Publication date: May 28, 2015
    Inventors: Fredrik JOABSSON, Margareta LINDEN, Krister THURESSON, Fredrik TIBERG
  • Publication number: 20150147309
    Abstract: The present invention relates to an allosteric non-inhibitory chaperone of the lysosomal acid alpha-glucosidase (GAA) for use in the treatment of a pathological condition characterized by a deficiency of the lysosomal acid alpha-glucosidase (GAA), to pharmaceutical composition thereof, to a method for increasing the activity of GAA in a subject and to a method for identifying an allosteric non-inhibitory chaperone for GAA.
    Type: Application
    Filed: June 6, 2013
    Publication date: May 28, 2015
    Inventors: Giancarlo Parenti, Caterina Porto, Marco Moracci, Maria Carmina Ferrara, Beatrice Cobucci-Ponzano, Generoso Andria
  • Publication number: 20150148418
    Abstract: Disclosed herein are methods for treating hair related disorders, including compounds that may be specific or modulate PPAR receptors.
    Type: Application
    Filed: June 25, 2014
    Publication date: May 28, 2015
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • Publication number: 20150148419
    Abstract: Isolated metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]-methyl]propanamide, methods for their use, and compositions containing the metabolites.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 28, 2015
    Inventors: Marlene Michelle Dressman, Deepak Phadke
  • Patent number: 9040553
    Abstract: The present invention provides a process for the synthesis of substituted phenoxymethylpropionic acid and related compounds. The compounds are useful for inhibiting the formation of AGEs (Advanced Glycation End Products).
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: May 26, 2015
    Assignee: CELL VIABLE CORPORATION
    Inventors: Iraj Lalezari, Jill Fabricant
  • Publication number: 20150141514
    Abstract: An agent for enhancing NO production, comprising citrulline or a salt thereof and serine or a salt thereof as an active ingredient. An agent for preventing or ameliorating vascular endothelial malfunction, comprising citrulline or a salt thereof and serine or a salt thereof as an active ingredient. An agent for preventing or ameliorating a symptom caused by vascular endothelial malfunction, comprising citrulline or a salt thereof and serine or a salt thereof as an active ingredient.
    Type: Application
    Filed: June 28, 2013
    Publication date: May 21, 2015
    Inventors: Masahiko Morita, Miho Yin Komatsu, Takahiro Hara
  • Publication number: 20150140076
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier
  • Publication number: 20150140075
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier
  • Publication number: 20150141506
    Abstract: Compounds particularly for use in an autoimmune inflammatory disease and especially the treatment of inflammatory bowel disease have the absolute stereochemistry and formula: In some cases R1 is leucine and R is selected from: OH, OCH3, OCH2CH3, OCH2CH2CH3, NH2, NHCH2CH2OH, NHCH3, N(CH3)2, NH(4-OH-3-benzoic acid).
    Type: Application
    Filed: May 23, 2013
    Publication date: May 21, 2015
    Inventors: Neil Frankish, Helen Sheridan
  • Publication number: 20150140081
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier
  • Publication number: 20150140078
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier
  • Publication number: 20150140079
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier
  • Publication number: 20150140093
    Abstract: Compositions, methods of making, and methods of using nanoclusters in which the nanoclusters comprise a plurality of nanoparticles having a core of nanoparticles arranged such that the surfaces of the nanoparticles contact adjacent nanoparticles, the nanoparticles comprise an active ingredient, and the nanocluster has a mass median aerodynamic diameter of from about 0.25 ?m to about 20 ?m.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 21, 2015
    Inventors: Cory J. Berkland, Lianjun Shi, Nashwa El Gendy, Carl Plumley, Mark Bailey
  • Publication number: 20150140080
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier
  • Publication number: 20150140077
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier
  • Patent number: 9034924
    Abstract: Provision of an N-acyl basic amino acid dispersion superior in dispersibility. The present invention provides a production method of an N-acyl basic amino acid dispersion having a pH of 2 to 12, comprising (1) a step of dissolving an N-acyl basic amino acid in a base solution, and (2) a step of mixing the obtained N-acyl basic amino acid solution with one or more equivalents of an acid relative to the base.
    Type: Grant
    Filed: July 10, 2012
    Date of Patent: May 19, 2015
    Assignee: AJINOMOTO CO., LTD.
    Inventors: Koichiro Sagawa, Bruce W. Gesslein, Kseniya Popova, Eiko Oshimura, Naoaki Ikeda, Tomokazu Kamidoi
  • Publication number: 20150133527
    Abstract: Methods are provided herein for treating cardiac arrhythmias, such as for treating an arrhythmia syndrome, for example Brugada syndrome, in a subject. In some embodiments, the methods include selecting a subject with Brugada syndrome and administering to the subject an effective amount of an agent that increases the expression or activity of SIRT1 in the subject. In some embodiments, the agent increases Nav1.5 activation. In some embodiments, the agent increases the expression or activity of SRIT1 and increases Nav1.5 activation.
    Type: Application
    Filed: May 6, 2013
    Publication date: May 14, 2015
    Inventors: Barry London, Kaikobad J. Irani
  • Publication number: 20150133515
    Abstract: This invention relates generally to integrin ligand discovery and to a method of integrin ligand discovery based upon induction of ligand-induced epitopes. Such ligands have the potential to be active agent as anti-inflammatory, anti-angiogenesis and/or anti-thrombotic agents and for the treatment of integrin mediated diseases and/or conditions.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 14, 2015
    Inventors: ALEXANDRE CHIGAEV, LARRY A. SKLAR
  • Publication number: 20150133556
    Abstract: The present invention relates to (1S,2S,3S,4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentyl-1-carboxylic acid hydrates compounds, preparing methods thereof, pharmaceutical compositions containing said compounds and preparing methods thereof, and the clinical uses of said compounds as neuramidinase inhibitors for anti-influenza.
    Type: Application
    Filed: October 10, 2014
    Publication date: May 14, 2015
    Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A., China
    Inventors: Song LI, Wu ZHONG, Zhibing ZHENG, Xinbo ZHOU, Junhai XIAO, Yunde XIE, Lili WANG, Xingzhou LI, Guoming ZHAO, Xiaokui WANG, Hongying LIU